Home
IPO Review by Dilip Davda
Menu
Home
Markets
IPO Review by Dilip Davda
India Inc
Economy and Politics
Intellect Views
Brands & Lifestyle
Pages
Home
IPO Review by Dilip Davda
Categories
Home
Markets
IPO Review by Dilip Davda
India Inc
Economy and Politics
Intellect Views
Brands & Lifestyle
Tag:
US Generics
India Inc
Cipla’s record India sales are not enough to offset weaker US business
Team Finance Intellect
—
October 28, 2026
comments off
Cipla’s profit fell by more than a third, missing estimates. Its Indian business had a record quarter, but lower US revenue and narrower margins dragged down overall earnings. Cipla reported consolidated net...
Read more »